8-K

                                  UNITED STATES
                     SECURITIES AND EXCHANGE  COMMISSION
                                 Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported) May 26, 2006

                          MEDISCIENCE TECHNOLOGY CORP.

             (Exact name of registrant as specified in its charter)

        NEW JERSEY                      0-7405                   22-1937826

(State or other jurisdiction          (Commission              (IRS Employer
       of incorporation)              File Number)           Identification No.)


1235 Folkestone Way, P.O. Box 598, Cherry Hill, New Jersey            08034

        (Address of principal executive offices)                    (Zip Code)

       Registrant's telephone number, including area code (215) 485 0362

         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2- below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17
    CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17CFR240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13 e-4(c) under the
    Exchange Act (17 CFR 240.13 e-4(c))



Section 8 Other events

Item 8.01. Other Events.

On May. 26, 2006 Registrant reports FDA approval March 29, 2006 of registrants
proposed clinical investigation as a nonsignificant risk (NSR) device study.
Registrant submitted protocol for a pilot study for the C-D Ratiometer entitled
"A Multicenter Pilot study to establish the Safety and Parameters of Efficacy of
an Optical Biopsy Device (CDR) for Cancer Detection of Cervix Preliminary to a
Pivotal Study." (see report exhibit 99.2) This disclosure is intended to
satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as
well as all applicable and presently effective Sarbanes-Oxley disclosure
requirements under Regulation G.


Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

99.1   FDA letter dated March 31, 2006



                                   SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized on May 26, 2006

                                        MEDICSCIENCE TECHNOLOGY CORPORATION

                                        By: Peter Katevatis
                                            ---------------
                                        Name: Peter Katevatis
                                        Title: Chairman of the Board and
                                        Chief Executive Officer





                                  Exhibit Index

Exhibit No.     Description
- --------------------------------------------------------------------------------
99.1            FDA letter dated  March  31, 2006

EX-99.1

DEPARTMENT OF HEALTH &. HUMAN SERVICES                     Public Health Service

[LOGO] Food and Drug Administration 9200 Corporate Boulevard
       Rockville MD 20850
       3 I 2C06

Mediscience Technology Corporation
c/o Robert Schiff, Ph.D. RAC
President
Schiff & Company
1129 Bloomfield Avenue
WEST CALDWELL NJ 07006



Re: I040553/S003 and S004
Dated: January 4 and 17, 2006
Received: January 5 and 19, 2006
Q060019
Feasibility Study of Optical Biopsy Device for Cervical Cancer Detection
Request for Determination about Significant Risk Investigation

Dear Dr. Schiff:

The Food and Drug Administration (FDA) has reviewed your submission, dated
January 4, 2006, proposing a protocol for a pilot study for the C-D Ratiometer
entitled "A Multicenter Pilot study to establish the Safety and Parameters of
Efficacy of an Optical Biopsy Device (CDR) for Cancer Detection of Cervix
Preliminary to a Pivotal Study."FDA has determined that your proposed clinical
investigation is a nonsignificant risk (NSR) device study because it does not
meet the definition of a significant risk (SR) device under ss. 812.3(m) of the
investigational device exemptions (IDE) regulation (21 CFR 812, enclosed).

However, this decision is based on a specific worst case scenario for UV
exposure at a single measurement at 380 and 340 run and two exposures each at
300 and 289 run. If you anticipateexceeding this worst case scenario by
delivering multiple exposures at 380 nm or any other wavelength, a new worst
case scenario should be identified and submitted with a revised safety analysis.

An IDE application is not required to be submitted to, or approved by, FDA for a
NSR study. A NSR study is, however, subject to the abbreviated requirements
described in ss. 812.2(b) of the IDE regulation. The abbreviated requirements
stipulate that the sponsor of the investigation must label the device in
accordance with ss. 812.5; obtain institutional review board approval of the
investigation as a NSR study; ensure that each investigator obtains informed
consent from each subject under the investigator's care; comply with the
monitoring requirements of ss. 812.46; maintain records required under ss.
812.140(b)(4) and (5) and file the reports required under ss. 812.150(b)(1)
through (3) and (5) through (10); and ensure that participating investigators
maintain the records required by ss. 812.140(a)(3)(i) and file the reports
required under ss. 812.150(a)(1), (2), (5) and (7).



Under the abbreviated IDE requirements, a sponsor must also comply with the
prohibitions against promotion and other practices as identified in ss. B 12.7.
According to this section of the regulation, the sponsor of a NSR study,
investigator, or any person acting for or on behalf of the sponsor or
investigator is prohibited from promoting or test marketing the investigational
device until after FDA has approved the device for commerciai distribution;
commercializing the device by charging a price greater than that necessary to
recover the cost of manufacture, research, development, and handling; unduly
prolonging the investigation; and representing the investigational device as
being safe or effective for the purposes for which it is being investigated.

If you have any questions regarding our NSR detennination or the abbreviated IDE
requirements, please contact Mridulika Virmani, Ph.D. at (301) 594-1180.

                                             Sincerely yours,


                                             /s/ Nancy C. Brogdon
                                             Nancy C. Brogdon
                                             Director, Division of Reproductive,
                                                Abdominal, and Radiological
                                             Devices Office of Device
                                             Evaluation Center for Devices
                                             and Radiological Health

Enclosure

IDE Regulation (21 CFR, Part 812)